



Renate Kain,
Project coordinator

January 20th, 2016, 8.30 a.m.
Van Swieten Saal,
Medical University of Vienna



RELENT has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 668036.

Department of Pathology

Department of Pathology

Invitation

Personalized Medicine for Autoimmune diseases

H2020 project RELENT – Understanding common mechanisms of diseases and their relevance in co-morbidities

www.meduniwien.ac.at

Contact

Renate Kain
Clinical Institute of Pathology
Phone: +43 (0)1 40400 – 36810
Email: renate.kain@meduniwien.ac.at

Administrative Project Office
GABO:mi Gesellschaft für Ablauforganisation:
milliarium mbH & Co. KG
Natascha Perera
Tel: +49 89 288104-28
Email: natascha.perera@gabo-mi.com

Severe autoimmune and inflammatory diseases currently need to be treated with long-term immunosuppressive drugs that have significant side effects. Despite this, the outcome for individual patients varies considerably. We currently have no means of distinguishing from the outset which patients will suffer from frequent relapses of their disease – and therefore need intensive early treatment – from those who will not. The RELENT project will apply an entirely novel approach to systematically define common disease mechanisms in autoimmunity, involving a fast and high throughput discovery and validation process. By combining clinical and serological data with genetic and transcriptomic signatures to unravel the molecular mechanisms that determine disease outcome, we will be able to develop customised health care for people suffering from autoimmune disorders


RELENT aims to shed light on the course and mechanisms of diseases, such as rheumatoid arthritis and vasculitis, and to develop improved diagnostics and intervention strategies with the expected impact of delaying the onset of chronic autoimmune diseases.

All academic partners of the RELENT consortium will present their research leading to RELENT.

Project facts

RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities (RELENT, grant agreement no. 668036) is a multidisciplinary group of nine scientific partners and four SMEs from Europe, US and Australia funded by the European Union's Horizon 2020 research and innovation Program. RELENT started on 1st November 2015 and is coordinated by Renate Kain, Medical University of Vienna.

- RELENT has 13 partners, 6 from European countries and 1 each from USA and Australia
- The overall aim of RELENT is to develop individualised treatments for autoimmune diseases
- Nearly 6 Million Euros in project funding provided by the European Commission (H2020)
- RELENT is coordinated by Renate Kain from the Medical University Vienna
- 4.5 years of funding for the project started on 1/11/2015



Programme

8.30 – 9.00 a.m.

Address of Welcome

Renate Kain, Coordinator of RELENT, Medical University of Vienna, Austria

Markus Müller, Rector of the Medical University of Vienna, Austria

9.00 – 9.25 a.m.

Evidence for distinct genetic contributions to prognosis and susceptibility in Crohn's disease

Paul Lyons, University of Cambridge, Great Britain

9.25 – 9.50 a.m.

Immune checkpoint molecules determine switch to vasculitis in an aged immune system

Elisabeth Brower, Peter Heeringa, Academisch Ziekenhuis Groningen, the Netherlands

9.50 – 10.15 a.m.

PR3, a target and trigger of autoimmune-mediated inflammation

Dieter E. Jenne, Helmholtz Zentrum München, Germany

10.15 – 10.40 a.m.

The role of kidney DCs in the progression of nephritis

Christian Kurts, University Clinics Bonn, Germany

10.40 – 11.05 a.m.

Targeting MHC II in autoimmune disease

Hans-Joachim Anders, Ludwig-Maximilian-University München, Germany

11.05 – 11.30 a.m.

Coffee Break

11.30 – 11.55 a.m.

Human Protein Atlas enabled proteomic profiling of body fluids

Peter Nilsson, KTH Royal Institute of Technology, Sweden

11.55 a.m. – 12.20 p.m.

ANCA-associated vasculitis: how can we address clinically relevant questions?

Ulrich Specks, Mayo Clinic, USA

12.20 – 12.45 p.m.

Autoimmunity and cellular immunity in ANCA-associated glomerulonephritis

A. Richard Kitching, Monash University, Melbourne, Australia